Expression and significance of high-risk HPV16/18E6 in lung adenocarcinoma
- Author:
- No author available
- Journal Title:
- Chinese Journal of Health Management
- Issue:
- 3
- DOI:
- 10.3760/cma.j.cn115624-20200313-00155
- Key Word:
- 人乳头瘤病毒;肺腺癌;耐药性;Human papillomavirus;Lung adenocarcinoma;Resistance
Abstract： Objective:To analyze the expression and clinical significance of human papillomavirus (HPV) 16/18E6 in lung adenocarcinoma tissues and adjacent specimens.Methods:Sixty patients with pathologically confirmed lung adenocarcinoma treated with surgical resection were included in the study. To determine the expression of HPV16/18 E6, carcinoma specimens and adjacent tissues were collected and detected using immunohistochemistry. The χ 2 test was used to analyze the relationship between HPV16/18 E6 expression and the clinical features of lung adenocarcinoma. Using the cell transfection technique, the A549 lung adenocarcinoma cell line with high HPV16/18E6 expression was established, and the differences in cisplatin resistance between the E6, control (Ctl), and A549 groups were compared using the MTT assay. Results:Of the 60 cases, 29 (48%) were male and 31 (52%) were female, with an average age of (55.5±2.4) years. In lung adenocarcinoma specimens, the positive expression rate of HPV16/18 E6 was 48% (29/60), which was higher than that observed in adjacent tissues (18%; 11/60), demonstrating a statistically significant difference (P<0.05 ); the differences between the positive expression rate of HPV16/18E6 and TNM stage, age, gender, smoking, and tumor size were not statistically significant. In the E6 A549 lung adenocarcinoma group, cisplatin resistance was higher than that in the Ctl and A549 groups, demonstrating a statistically significant difference (P<0.05 ). Finally, the half-maximal inhibitory concentration (IC 50) of cisplatin in E6 (111 mg/L)was higher than that in Ctl(75 mg/L) and A549(79 mg/L) groups, demonstrating a statistically significant difference (P<0.05 ).Conclusions:High-risk HPV16/18E6 has a higher positive expression rate in lung adenocarcinoma, independent of TNM stage, age, gender, smoking, and tumor size, and may influence resistance to chemotherapy drugs.
- [1]闫滢,李明,胡冰,等.晚期非小细胞肺癌乳头瘤病毒感染状况及其与 P16表达的关联性研究[J].2016,(6).
- [2]刘俊宝,徐珍,郭亚花,等.HPV DNA、HPV E6蛋白联合检测筛查宫颈癌的应用价值[J].2017,(7).
- [3]Tara A. Berman,John T. Schiller.Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases[J].2017,123(12).
- [4]Philp, Lauren,Jembere, Nathaniel,Wang, Li,etc.Pap tests in the diagnosis of cervical cancer: Help or hinder?[J].2018,150(1).
- [5]So Hyeon, Bak,Hyunjin, Park,Ho Yun, Lee,etc.Imaging genotyping of functional signaling pathways in lung squamous cell carcinoma using a radiomics approach.[J].2018,8(1).
- [6]Yu, Yan,Liu, Xiaofei,Yang, Yuxuan,etc.Effect of FHIT loss and p53 mutation on HPV-infected lung carcinoma development[J].2015,10(1).
- [7]S, De Flora,S, La Maestra.Epidemiology of cancers of infectious origin and prevention strategies.[J].2015,56.
- [8]谢平,白帆,张杰,等.HPV16/18DNA、Bcl-2、Survivin mRNA在宫颈癌组织中的表达及其临床意义[J].2015,(3).
- [9]Planchard, David,Sullivan, Ivana.ALK inhibitors in non-small cell lung cancer: the latest evidence and developments[J].2016,8(1).
- [10]Xiuzhi, Zhou,Li, Cai,Junjie, Liu,etc.Analyzing EGFR mutations and their association with clinicopathological characteristics and prognosis of patients with lung adenocarcinoma.[J].2018,16(1).
- [11]Yang S,Xu P,Zeng G,etc.Grhl2 deficiency impairs otic development and hearing ability in a zebrafish model of the progressive dominant hearing loss DFNA28.[J].2011,20(16).
- [12]Alexander C,Sun,Enrique,Alvarez-Fontecilla,A G,Venkatesh,etc.High-Density Redox Amplified Coulostatic Discharge-Based Biosensor Array.[J].2018,53(7).
- [13]Walentin, Katharina,Hinze, Christian,Werth, Max,etc.A Grhl2-dependent gene network controls trophoblast branching morphogenesis[J].2015,142(6).
- [14]Namrata, Rastogi,Shivali, Duggal,Shailendra Kumar, Singh,etc.Proteasome inhibition mediates p53 reactivation and anti-cancer activity of 6-gingerol in cervical cancer cells.[J].2015,6.
- [15]Soucheray, Margaret,Krogan, Nevan J.,Grandis, Jennifer R.,etc.Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer[J].2018,78(9).
- [16]Pim D,Banks L.Interaction of viral oncoproteins with cellular target molecules: infection with high-risk vs low-risk human papillomaviruses.[J].2010,118(6/7).
- [17]Colombara Danny V.,Manhart Lisa E.,Carter Joseph J.,etc.Prior human polyomavirus and papillomavirus infection and incident lung cancer: a nested case–control study[J].2015,26(12).
- [18]Min-Che, Tung,Po-Lin, Lin,Ya-Wen, Cheng,etc.Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.[J].2016.
- [19]Goldstraw, Peter,Chansky, Kari,Crowley, John,etc.The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer[J].2016,11(1).
- [20]Camille Ragin,Monisola Obikoya-Malomo,Sungjin Kim,etc.HPV-associated lung cancers: an international pooled analysis.[J].2014,35(6).
- [21]Isa, Shun-Ichi,Kurahara, Yu,Yamamoto, Satomi,etc.Molecular analysis of human papillomavirus in never-smokers with non-small cell lung cancer[J].2015,9(2).
- [22]Kari J. Syrjänen.Condylomatous Changes in Neoplastic Bronchial Epithelium[J].1979,38(5).